Login to Your Account

Gilead Pushes Cancer Pipeline; Enters Phase III with PI3K Drug

By Catherine Shaffer
Staff Writer

Thursday, May 3, 2012
Gilead Sciences Inc. began a Phase III trial of its PI3K inhibitor, GS-1101, in chronic lymphocytic leukemia (CLL). If successful, the company could add a cancer candidate to its powerhouse lineup of products currently led by its HIV and hepatitis C virus franchises.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription